---
layout: default
title: Anastrozole
parent: 僅模型預測 (L5)
nav_order: 348
evidence_level: L5
indication_count: 6
---

# Anastrozole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Anastrozole: No TxGNN Predictions Available — Evaluation Incomplete

## One-Sentence Summary

Anastrozole (DrugBank ID: DB01217) is a well-known aromatase inhibitor established in breast cancer therapy. The current Evidence Pack contains **no TxGNN predicted indications**, and two high-severity data gaps — missing mechanism of action (DG002) and missing safety/label data (DG001, Blocking) — prevent this evaluation from proceeding. A data remediation step is required before a repurposing analysis can be completed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not captured in Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No supporting predictions or studies |
| Taiwan Market Status | Not marketed（未上市） |
| Number of Taiwan Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available in this Evidence Pack. A mechanistic rationale for repurposing cannot be presented at this stage.

Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on established pharmacology, Anastrozole is a selective aromatase (CYP19A1) inhibitor that suppresses peripheral estrogen biosynthesis, and its efficacy in hormone receptor-positive breast cancer has been demonstrated in multiple large Phase 3 trials. However, until the TxGNN pipeline generates predicted indications for this drug, mechanistic applicability to any new indication cannot be evaluated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no TxGNN predicted indication is available to define the search scope.

---

## Literature Evidence

Currently no related literature available — no TxGNN predicted indication is available to define the search scope.

---

## Taiwan Market Information

Anastrozole has no registered licenses in the Taiwan TFDA database as of the query date (2026-03-24).

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| — | — | — | No records found in TFDA database |

> **Note:** Anastrozole is commercially available as Arimidex® (AstraZeneca) in multiple markets. If the TFDA query used the INN "ANASTROZOLE" and returned 0 results, it is advisable to re-query using the brand name or common transliterations before concluding the drug is absent from the Taiwan market.

---

## Cytotoxicity

Anastrozole is an antineoplastic agent (breast cancer treatment); this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted / Hormonal therapy — Aromatase inhibitor; **not** a conventional cytotoxic agent |
| Myelosuppression Risk | Low — aromatase inhibitors do not typically cause clinically significant bone marrow suppression |
| Emetogenicity Classification | Low |
| Monitoring Items | Bone mineral density (osteoporosis and fracture risk), lipid profile, liver function tests, musculoskeletal symptoms (arthralgia, myalgia) |
| Handling Protection | Standard precautions apply; cytotoxic handling protocols not required |

---

## Safety Considerations

Please refer to the package insert for safety information.

TFDA package insert data has not been retrieved (DG001, severity: **Blocking**). Key warnings, contraindications, and drug-drug interaction data are all unavailable in this Evidence Pack. Full safety profiling is required before any repurposing evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is critically incomplete — the TxGNN pipeline returned no predicted indications for Anastrozole, and two data gaps (DG001 Blocking, DG002 High) prevent safety and mechanism analysis. There is no prediction to evaluate.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for Anastrozole (DB01217) to generate candidate indications — this is the prerequisite for the entire report
- **Retrieve MOA data from DrugBank API** (resolves DG002; needed for mechanism-of-action section)
- **Download and parse the TFDA package insert** for key warnings and contraindications (resolves DG001, Blocking; required for safety evaluation)
- **Re-verify Taiwan market status** — TFDA query returned 0 results; confirm whether the drug is marketed under the brand name Arimidex® or a generic before concluding it is not marketed in Taiwan
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

